News

Berlin, 5 February 2026: TRI Conference in Berlin 16-18 September 2026

We proudly announce the 20th Tinnitus Research Initiative (TRI) Conference 2026.The Tinnitus Zentrum Charité – Universitätsmedizin Berlin and the German Foundation Tinnitus & Hearing Charité are jointly organizing this international conference, which will take place in Berlin from 16 – 18 September 2026. Hundreds of world-leading tinnitus experts will gather at Campus Charité Mitte in Berlin to share the latest in research, diagnosis and treatment of tinnitus. The interdisciplinary exchange of knowledge between ENT, neurology, audiology and psychology will help to better understand how tinnitus originates in order to alleviate the symptoms and, in the future find a cure for it. The scientific directors of the conference are Professor Birgit Mazurek and Professor Berthold Langguth.

All experts from Europe and around the world are cordially invited to register online for participation. The programme, all information on ticket prices, and the link to the registration plattform can be found here.

Berlin, 6 December 2025: Research Prize Tinnitus and Hearing

This year, the foundation once again received numerous applications from Germany and other European countries for the Research Prize Tinnitus and Hearing. The Scientific Advisory Board reviewed all submissions and ultimately selected Dr. rer. nat. Konstantin Tziridis as ths years winner. The postdoctoral researcher and scientific staff member for neurobiological basic research – Experimental ENT Medicine at the ENT Clinic of the Friedrich-Alexander University Erlangen-Nürnberg (FAU) – received the highest rating for his study“A Single Dose of AC102 Reverts Tinnitus in Noise-Exposed Mongolian Gerbils by Restoring Ribbon Synapses.”

AC102 is a promising, new compound from AudioCure Pharma GmbH that may protect hair cells from degeneration and promote the restoration of neural connections (synapses) from the inner ear to the brain. Following a successful Phase 1 study, AC102 is currently being tested in a European Phase 2 study in patients with sudden hearing loss, where it is injected directly into the middle ear and could potentially be more effective than, for example, cortisone.

The Advisory Board emphasized the outstanding scientific and clinical relevance of the study and expressed it’s hope that this award represents another step toward an effective medical treatment for tinnitus patients.

Welcome to EUTINNET, the European Tinnitus Network

As a member, you join a diverse group of tinnitus and hearing loss organizations from across Europe, all focused on improving awareness, sharing research, and supporting those affected by tinnitus and related conditions. By connecting with experts, researchers and patient communities, you contribute to advancing treatment options and fostering collaboration across borders. Your involvement helps to strengthen the network’s mission of promoting knowledge transfer and improving the quality of life for those impacted by tinnitus.